Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflas
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The company has paid an Interim Environmental Damage Compensation of Rs. 3.40 lakh to GPCB
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
The brand Magtein by Threotech has a sales value of approximately US $438 million
Morepen Laboratories approves hiving off of medical devices business
atulya keratin & wheat protein shampoo has force of natural ingredients like extract of wheat, fenugreek, reetha & almond oil
The conference featured comprehensive discussions, field visits, and knowledge-sharing sessions addressing different aspect of major NCDs
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
Subscribe To Our Newsletter & Stay Updated